Neurophysiologic Biomarkers in Neuropsychiatric Disorders Etiologic and Treatment Considerations

Master Neurophysiologic Biomarkers: Bridging Biomarkers, Mechanisms, and Treatment in Psychiatry

Gain a comprehensive perspective on the role of neurophysiological biomarkers in neuropsychiatric illness—integrating cutting-edge science, regulatory insight, and therapeutic innovation. Edited by leading experts Daniel C. Javitt and James C. McPartland, this volume maps the translation from biomarker discovery to clinical decision-making across major mental health disorders.

Key Features:

1. Regulatory & Translational Framework: Explores biomarker classification per the FDA’s BEST scheme and the 21st Century Cures Act, guiding biomarker use for susceptibility, diagnosis, prognosis, monitoring, pharmacodynamics, response, and safety.

2. Disorder-Specific Deep Dives: Detailed chapters cover schizophrenia, autism spectrum disorder, depression, Parkinson’s disease and other syndromes—highlighting functional connectivity, event‑related potentials, gamma oscillations, sleep biomarkers, mismatch negativity, and more.

3. Preclinical to Clinical Continuum: Includes studies in non-human primates and rodent analog models to advance translational validity, supporting researchers and clinical investigators alike.

4. Advanced Methodologies: Covers fMRI, magnetoencephalography (MEG), time–frequency analysis, source localization, and circuit-level approaches to develop robust neurophysiological markers.

5. Multi–Stakeholder Relevance: Designed to inform clinicians, neuroscientists, and pharmaceutical developers, this volume purposefully aligns scientific rigor with drug development priorities.

With over 800 pages of in-depth analysis and 26 chapters contributed by world authorities, this first edition (released in November 2024) is a must-have for scientists, clinicians, and translational researchers focused on biomarker-driven discovery and treatment development in psychiatric and neurodevelopmental disorders.